GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Margin of Safety % (DCF Earnings Based)

HighTide Therapeutics (HKSE:02511) Margin of Safety % (DCF Earnings Based) : N/A (As of Jun. 07, 2024)


View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

HighTide Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.


Competitive Comparison of HighTide Therapeutics's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, HighTide Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HighTide Therapeutics's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.



HighTide Therapeutics Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


HighTide Therapeutics (HKSE:02511) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Executives
Ma Lixiong 2101 Beneficial owner
Liu Liping 2101 Beneficial owner
Li Li 2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao 2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc. 2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p 2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited 2101 Beneficial owner
Hepalink (hong Kong) Limited 2201 Interest of corporation controlled by you
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 2501 Other
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited 2101 Beneficial owner
Lai Hoi Man 2201 Interest of corporation controlled by you
Hongtu Capital Limited 2101 Beneficial owner

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines